全国中西医整合治疗幽门螺杆菌相关“病-证”共识

2018-07-10 中国消化科相关专家小组(统称) 中华医学杂志.2018.98(26):2066-2072.

随着幽门螺杆菌治疗的广泛开展,其耐药性增加,根除率逐渐降低,有效治疗幽门螺杆菌感染面临着挑战。近20年来,幽门螺杆菌治疗方案从三联变为四联,疗程不断延长,某些抗生素的剂量不断增加,但疗效提高有限,且副作用随之增加,不少患者治疗反复失败。当前幽门螺杆菌治疗已经进人瓶颈时期,寻求符合中国特色的幽门螺杆菌治疗方案,开创幽门螺杆菌治疗新路径是幽门螺杆菌治疗必由之路近10多年来,国内已有一系列中西医整合治疗

中文标题:

全国中西医整合治疗幽门螺杆菌相关“病-证”共识

发布日期:

2018-07-10

简要介绍:

随着幽门螺杆菌治疗的广泛开展,其耐药性增加,根除率逐渐降低,有效治疗幽门螺杆菌感染面临着挑战。近20年来,幽门螺杆菌治疗方案从三联变为四联,疗程不断延长,某些抗生素的剂量不断增加,但疗效提高有限,且副作用随之增加,不少患者治疗反复失败。当前幽门螺杆菌治疗已经进人瓶颈时期,寻求符合中国特色的幽门螺杆菌治疗方案,开创幽门螺杆菌治疗新路径是幽门螺杆菌治疗必由之路近10多年来,国内已有一系列中西医整合治疗幽门螺杆菌的多中心临床研究,取得了很好疗效,得到了泛交流和应用,这些研究为制定《全国中西医整合治疗幽门螺杆菌相关“病一证”共识》(下称“共识”)奠定了基础,提供了理论依据。 

拓展指南:幽门螺杆菌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=全国中西医整合治疗幽门螺杆菌相关“病-证”共识)] GetToolGuiderByIdResponse(projectId=1, id=166cc1c00161a5a4, title=全国中西医整合治疗幽门螺杆菌相关“病-证”共识, enTitle=, guiderFrom=中华医学杂志.2018.98(26):2066-2072., authorId=null, author=, summary=随着幽门螺杆菌治疗的广泛开展,其耐药性增加,根除率逐渐降低,有效治疗幽门螺杆菌感染面临着挑战。近20年来,幽门螺杆菌治疗方案从三联变为四联,疗程不断延长,某些抗生素的剂量不断增加,但疗效提高有限,且副作用随之增加,不少患者治疗反复失败。当前幽门螺杆菌治疗已经进人瓶颈时期,寻求符合中国特色的幽门螺杆菌治疗方案,开创幽门螺杆菌治疗新路径是幽门螺杆菌治疗必由之路近10多年来,国内已有一系列中西医整合治疗, cover=, journalId=null, articlesId=null, associationId=1327, associationName=中国消化科相关专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Tue Jul 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>随着幽门螺杆菌治疗的广泛开展,其耐药性增加,根除率逐渐降低,有效治疗幽门螺杆菌感染面临着挑战。近20年来,幽门螺杆菌治疗方案从三联变为四联,疗程不断延长,某些抗生素的剂量不断增加,但疗效提高有限,且副作用随之增加,不少患者治疗反复失败。当前幽门螺杆菌治疗已经进人瓶颈时期,寻求符合中国特色的幽门螺杆菌治疗方案,开创幽门螺杆菌治疗新路径是幽门螺杆菌治疗必由之路近10多年来,国内已有一系列中西医整合治疗幽门螺杆菌的多中心临床研究,取得了很好疗效,得到了泛交流和应用,这些研究为制定《全国中西医整合治疗幽门螺杆菌相关“病一证”共识》(下称“共识”)奠定了基础,提供了理论依据。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>幽门螺杆菌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=93bff1c0015626ad" title="2017年台湾幽门螺杆菌共识:关于幽门螺杆菌感染的临床管理、筛选治疗和监控以改善台湾地区胃癌控制的共识" target=_blank>2017年台湾幽门螺杆菌共识:关于幽门螺杆菌感染的临床管理、筛选治疗和监控以改善台湾地区胃癌控制的共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=930e81c001a8057d" title="2017 IHPWG共识:成人幽门螺杆菌感染的诊断和治疗" target=_blank>2017 IHPWG共识:成人幽门螺杆菌感染的诊断和治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ccfef1c001a6885b" title="“第五次全国幽门螺杆菌感染处理共识报告”解读" target=_blank>“第五次全国幽门螺杆菌感染处理共识报告”解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=98e421c001a68eda" title="第五次全国幽门螺杆菌感染处理共识报告" target=_blank>第五次全国幽门螺杆菌感染处理共识报告</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=baf381c001a52226" title="【专题】幽门螺杆菌精华指南在手,轻松解决胃病问题" target=_blank>【专题】幽门螺杆菌精华指南在手,轻松解决胃病问题</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%B9%BD%E9%97%A8%E8%9E%BA%E6%9D%86%E8%8F%8C" target=_blank>有关幽门螺杆菌更多指南</a></ul>, tagList=[TagDto(tagId=77776, tagName=中西医整合治疗), TagDto(tagId=77777, tagName=幽门螺杆菌相关“病-证”)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7262, appHits=517, showAppHits=0, pcHits=5763, showPcHits=1887, likes=133, shares=22, comments=5, approvalStatus=1, publishedTime=Thu Jul 12 22:07:21 CST 2018, publishedTimeString=2018-07-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 12 22:07:21 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:03:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=全国中西医整合治疗幽门螺杆菌相关“病-证”共识)])
全国中西医整合治疗幽门螺杆菌相关“病-证”共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=946830, encodeId=045094683075, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=pKOZAU0JVu37GqeTtqD7Mw&s=100&t=1555758717, createdBy=80245360461, createdName=天南星9178, createdTime=Tue Mar 09 15:29:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808768, encodeId=36ed808e682e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=865d2505886, createdName=xusongplx, createdTime=Fri Aug 14 09:28:10 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331157, encodeId=e29133115e34, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 12 23:07:15 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2021-03-09 天南星9178

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=946830, encodeId=045094683075, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=pKOZAU0JVu37GqeTtqD7Mw&s=100&t=1555758717, createdBy=80245360461, createdName=天南星9178, createdTime=Tue Mar 09 15:29:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808768, encodeId=36ed808e682e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=865d2505886, createdName=xusongplx, createdTime=Fri Aug 14 09:28:10 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331157, encodeId=e29133115e34, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 12 23:07:15 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2020-08-14 xusongplx

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=946830, encodeId=045094683075, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=pKOZAU0JVu37GqeTtqD7Mw&s=100&t=1555758717, createdBy=80245360461, createdName=天南星9178, createdTime=Tue Mar 09 15:29:58 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808768, encodeId=36ed808e682e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=865d2505886, createdName=xusongplx, createdTime=Fri Aug 14 09:28:10 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331157, encodeId=e29133115e34, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 12 23:07:15 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 医者仁心5538

    学习了

    0